🇺🇸 FDA
Company

ALNYLAM

ALNYLAM PHARMACEUTICALS, INC.

ALNY pharma USA

Quick answer

ALNYLAM is a pharma company (ALNY) headquartered in CAMBRIDGE, MA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Givosiran

Acute Hepatic Porphyria

Phase 3 · small_molecule · completed

1 trials project

Lumasiran

Primary Hyperoxaluria

Phase 3 · small_molecule · completed

1 trials project

Lumasiran

Primary Hyperoxaluria Type 1

Phase 3 · small_molecule · completed

1 trials project

Nucresiran

Transthyretin Amyloidosis With Cardiomyopathy

Phase 3 · small_molecule · active

1 trials project

Nucresiran

Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

Phase 3 · small_molecule · active

1 trials project

Patisiran

Amyloidosis, Familial

Phase 3 · small_molecule · completed

1 trials project

Patisiran

Amyloidosis

Phase 3 · small_molecule · completed

1 trials project

Patisiran

Amyloidosis, Hereditary

Phase 3 · small_molecule · completed

1 trials project

Placebo

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Phase 3 · small_molecule · completed

1 trials project

Placebo

Primary Hyperoxaluria Type 1 (PH1)

Phase 3 · small_molecule · completed

1 trials project

Revusiran (ALN-TTRSC)

Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Phase 3 · small_molecule · completed

1 trials project

Vutrisiran

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Phase 3 · small_molecule · active

2 trials project

Zilebesiran

High Risk Cardiovascular Disease

Phase 3 · small_molecule · active

1 trials project

patisiran (ALN-TTR02)

TTR-mediated Amyloidosis

Phase 3 · small_molecule · completed

1 trials project

ALN-2232

Obesity

Phase 2 · small_molecule · active

1 trials project

ALN-4324

Type 2 Diabetes Mellitus (T2DM)

Phase 2 · small_molecule · active

1 trials project

ALN-4324

Obese or Overweight Healthy Volunteers

Phase 2 · small_molecule · active

1 trials project

ALN-6400

Hereditary Hemorrhagic Telangiectasia

Phase 2 · small_molecule · active

1 trials project

ALN-6400

Von Willebrand Disease (VWD)

Phase 2 · small_molecule · active

1 trials project

ALN-AAT02

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 2 · small_molecule · terminated

1 trials project

ALN-AGT01 RVR

Hypertension

Phase 2 · small_molecule · active

1 trials project

ALN-CC5

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2 · small_molecule · completed

1 trials project

ALN-KHK

Type 2 Diabetes Mellitus (T2DM)

Phase 2 · small_molecule · terminated

1 trials project

ALN-RSV01

Respiratory Syncytial Virus Infections

Phase 2 · small_molecule · completed

3 trials

Drugs (4)

drug

givosiran sodium

GIVLAARI

 drug

lumasiran sodium

OXLUMO

 drug

patisiran sodium

ONPATTRO

 drug

vutrisiran sodium

AMVUTTRA

Patents (8)

patent

US 12416006

Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods o

Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12404508

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12397013

Extrahepatic delivery

Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12385044

Modified double-stranded RNA agents

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12385043

Modified double-stranded RNA agents

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12378553

Modified double-stranded RNA agents

Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12364762

Biodegradable lipids for the delivery of active agents

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12350338

Biodegradable lipids for the delivery of active agents

Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)